Program
TQC2731
A development code. Also written as “TQC2731 injection”, “210mg of TQC2731 injection” and “420mg of TQC2731 injection”.
In Sino Biopharmaceutical's pipeline, TSLP单抗
. Its studies are mostly in Nasal Polyps · Asthma · Pulmonary Disease, Chronic Obstructive, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 73 open or running | phase 3since Feb 12, 2025 | Jun 2, 2021 | Dec 2026phase 2 · NCT06707883 |
- Named in Sino Biopharmaceutical’s own pipeline as
TQC2731
, phase 3, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 2, 2021First study: phase 1 study in Asthma Severe Persistent ControlledFirst studyNCT04923607 · 96 enrolled · China
- Jun 9, 2022Phase 2 study in AsthmaNCT05472324 · 205 enrolled · China
- Sep 1, 2023Phase 2 study in Nasal PolypsNCT06036927 · 80 enrolled · China
- May 30, 2024Phase 2 study in Chronic Rhinosinusitis With Nasal PolypsNCT06451640 · 59 enrolled · China
- Nov 25, 2024Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT06707883 · 258 enrolled · China
- Feb 12, 2025Phase 3 study in AsthmaNCT06829784 · 660 planned · China
- Jul 23, 2025Phase 3 study in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)NCT07107256 · 246 enrolled · China
Ahead
- Dec 2026Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT06707883
- Mar 2027Primary completion: phase 3 study in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)NCT07107256
- Dec 2027Primary completion: phase 3 study in AsthmaNCT06829784
TargetBeta
“TSLP单抗”the company's pipeline, read by Claude · source
Other programs on TSLP
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tezepelumabrule | AstraZeneca | phase 4 | 34 |
| tilrekimig | Pfizer | phase 3 | 11 |
| lunsekimig | Sanofi | phase 3 | 10 |
| felcorekibart | GlaxoSmithKline | phase 3 | 9 |
| SHR-1905 | Jiangsu HengRui Medicine | phase 3 | 7 |
| WIN378rule | windward-bio | phase 2 | 2 |
| CDX-622rule | Celldex Therapeutics | phase 1 | 2 |
| HXN-1013rule | Helixon Biotechnology (Suzhou) | phase 1 | 1 |
| HY6725rule | Newsoara Biopharma | phase 1 | 1 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07107256Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) · China | 3 | Active, not recruiting | Mar 2027 | 246 |
| NCT06829784Asthma · China | 3 | Recruiting | Dec 2027 | 660 |
| NCT06707883Pulmonary Disease, Chronic Obstructive · China | 2 | Active, not recruiting | Dec 2026 | 258 |
| NCT06451640Chronic Rhinosinusitis With Nasal Polyps · China | 2 | Completed | Oct 17, 2025 | 59 |
| NCT06036927Nasal Polyps · China | 2 | Completed | Feb 5, 2025 | 80 |
| NCT05472324Asthma · China | 2 | Completed | Mar 5, 2025 | 205 |
| NCT04923607Asthma Severe Persistent Controlled · China | 1 | UNKNOWN | Aug 25, 2023 | 96 |
How it is read
Names in the registry
- “TQC2731 injection”, 5 entries
- “210mg of TQC2731 injection”, 1 entry
- “420mg of TQC2731 injection”, 1 entry
- “TQC2731”, 1 entry
Codes read as this program: TQC2731.
Conditions, from the studies’ own filings
- Nasal Polyps, 3 studies
- Asthma, 3 studies
- Pulmonary Disease, Chronic Obstructive, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.